Human ADME Studies: Leveraging A Synthesis-To-Clinic® Approach To Rapidly Support Regulatory Approval

In this webinar, Iain Shaw, Senior Director of 14C Enabled Drug Development at Quotient Sciences, is joined by a panel of experts from our drug development, radiosynthesis and clinical pharmacology teams to answer questions around strategies for efficient human ADME study design. The benefits of leveraging a synthesis-to-clinic approach to rapidly support regulatory approval are discussed.